All In Biotech

Free tool

FAERS Monitor: Xerava

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211109 or its brand name (Xerava, Eravacycline Dihydrochloride). Reports on generic versions are filed under their own applications.

Reports

298

Serious

227

76% of reports

Hospitalization

85

Death reported

50

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use98
  • drug ineffective33
  • blood fibrinogen decreased29
  • thrombocytopenia18
  • nausea15
  • product use in unapproved indication15
  • diarrhoea14
  • multiple organ dysfunction syndrome14
  • condition aggravated12
  • coagulopathy11
  • hypofibrinogenaemia11
  • lactic acidosis11
  • pancreatitis11
  • drug intolerance10
  • hypertransaminasaemia10

Reports by year received

View as table
YearReports
201912
202010
202115
202229
202352
202441
202545
202694

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,861 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood fibrinogen decreasedSignal291840.81296.250,198
hypofibrinogenaemiaSignal11792.2442.17,832
hypertransaminasaemiaSignal10101.655.2897
coagulopathySignal1146.626.1447
multiple organ dysfunction syndromeSignal1434.920.9428
lactic acidosisSignal1124.013.4220
pancreatitisSignal1114.78.2127
thrombocytopeniaSignal1811.47.3161
off label useSignal987.96.7609
drug intoleranceSignal107.34.049
product use in unapproved indicationSignal154.32.635
condition aggravatedSignal122.81.612
drug ineffective331.81.311
diarrhoea141.50.92
nausea151.30.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.